Skip to content
iCo Therapeutics
  • iCo Therapeutics
  • About Us ▾
    • Our Vision and Strategy
    • Leadership and Board of Directors
    • Accomplishments
  • Current Assets ▾
    • The Problem of Drug Shortages
    • iCo-008
    • Oral Amphotericin B
  • Investor Information
  • Contact
  • iCo Articles

Sitemap

Sitemap

Pages

  • 2007 News Releases
  • 2007 News Releases
  • 2008 News Releases
  • 2008 News Releases
  • 2009 News Releases
  • 2009 News Releases
  • 2010 News Releases
  • 2010 News Releases
  • 2011 News Releases
  • 2011 News Releases
  • 2012 News Releases
  • 2012 News Releases
  • 2013 News Releases
  • 2013 News Releases
  • 2013 News Releases
  • 2014 News Releases
  • 2015 News Releases
  • 2016 News Releases
  • 2017 News Releases
  • 2018 News Releases
  • About iCo
  • About Vancouver
  • Accomplishments
  • AGM
  • Alliances & Global Licensing
  • Board of Directors
  • Careers
  • Careers
  • Careers
  • Clinical Trials
  • Contact Us
  • Corporate Overview
  • Corporate Overview
  • Corporate Overview
  • Corporate Overview
  • Corporate Overview
  • Corporate Overview
  • Corporate Overview
  • Corporate Video
  • Current Assets
  • Development Programs
  • Development Programs
  • Disclaimer
  • Events
  • FAQ
  • Get In Touch
  • How to Make Sure that Generic Drugs are Safe for Your Health?
  • iCo 007
  • iCo Therapeutics – Your Health Is Your Most Precious Asset
  • iCo-008
  • Investor Information: Articles
  • Investor Information: Financial Information
  • Investor Information: Presentations
  • Investor Information: Press Releases
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Investor Relations
  • Leadership and Board of Directors
  • Liver Failure – Symptoms, Medications, Prevention
  • Management Team
  • Media Coverage
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News and Media
  • News Releases
  • Newsroom
  • Oral Amphotericin B (“Amp B”)
  • Our Business Model
  • Overview
  • Overview
  • Partnering
  • Partnering Strategy
  • Pipeline
    • Clinical Trials
    • iCo-007
    • iCo-008
    • iCo-009
    • Oral Amphotericin B Delivery System
  • Pipeline
  • Pipeline
  • Pipeline
  • Pipeline
  • Pipeline
  • Presentations
  • Press Releases
  • Professional Advisors
  • Professional Advisors
  • Public information on the iDEAL study
  • Reports & Financials
  • Research
  • Science
  • Science
  • Sitemap
  • Strategic Advisory Board
  • Strategic Advisory Board
  • Terms of Use
  • The Problem of Drug Shortages
  • Upcoming Events

Posts by category

  • Category: 2007
    • iCo Therapeutics Inc. and Beanstalk Capital Ltd. Announce Completion of Arrangement
    • Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
    • Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc.
    • Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
    • iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema
    • iCo Therapeutics Announces Licensing Deal
    • Cambridge Antibody Tech. licenses monoclonal antibody for treatment of allergy disorders to iCo
  • Category: 2008
    • iCo Therapeutics Oral Amphotericin B Poster at AAPS
    • iCo Therapeutics Third Quarter Financial Results
    • iCo Therapeutics Oral Amphotericin B Effective Against Visceral Leishmaniasis
    • iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Pharmacokinetic Results
    • iCo Therapeutics Selected as Canada’s Top 10TM Competition Winner
    • iCo Therapeutics to Present at BioContact Québec
    • iCo Therapeutics Provides Interim Trial Results (Diffuse Diabetic Macular Edema)
    • iCo Therapeutics Outlines Steps to First iCo-009 Human Clinical Trial
    • iCo Therapeutics Second Quarter Financial Results
    • iCo Therapeutics Appoints Mr. Noel Hall and Dr. Christian Fibiger to Board
    • iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results
    • iCo Therapeutics Closes $1,140,450 Financing
    • iCo Therapeutics Announces $1,140,450 Financing
    • iCo Therapeutics First Quarter Financial Results
    • iCo Therapeutics Acquires Worldwide Rights to iCo-009 (Oral Amphotericin B)
    • iCo Therapeutics to Present at BioFinance 2008
    • iCo Therapeutics Year-End 2007 Financial Results
    • iCo Therapeutics iCo-007 Diabetic Macular Edema Poster Presentation at ARVO
    • iCo Therapeutics Announces iCo-009 (Oral Amphotericin B) FDA Meeting
    • iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal
    • iCo Therapeutics Provides iCo-008 Phase II Clinical Update
    • iCo Therapeutics Announces CMO Invited to Present at International Ocular Conference
    • iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Update
  • Category: 2009
    • iCo Therapeutics Grants Options to Directors, Officers and Employees
    • iCo Therapeutics Provides Phase 1 DME Clinical Trial Update and Phase 2 Trial Guidance
    • iCo Therapeutics iCo-007 Overview to be Presented at the 8th International Symposium on Ocular Pharmacology and Therapeutics
    • iCo Therapeutics Q3 2009 Financial Results
    • iCo Therapeutics Completes Final Tranche of $4,000,000 Brokered Private Placement
    • iCo Therapeutics Completes First Tranche of Brokered Private Placement
    • iCo Therapeutics Announces $4,000,000 Brokered Private Placement
    • iCo Therapeutics Signs Collaboration Agreement with The Consortium for Parasitic Drug Development
    • iCo Therapeutics Q2 2009 Financial Results
    • iCo Therapeutics Appoints Infectious Disease MD to Scientific Advisory Board
    • iCo Therapeutics Closes Non-Brokered Private Placement
    • iCo Therapeutics Diabetic Macular Edema Clinical Trial Update
    • iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment
    • iCo Therapeutics Positive Oral Amphotericin B Data Published in the Journal of Infectious Diseases
    • Shareholders Approve All Resolutions at iCo Therapeutics Annual General Meeting
    • iCo Therapeutics Q1 2009 Financial Results
    • iCo Therapeutics Year-End 2008 Financial Results
    • iCo Therapeutics to Present at BioFinance 2009
    • iCo Therapeutics Oral Anti-Parasitic Drug to be Presented at Global Health Symposia
    • iCo Therapeutics iCo-007 Second Cohort Results to be Presented at Cleveland Clinic Ocular Conference
    • iCo Therapeutics Grants Options to New Directors
    • iCo Therapeutics iCo-007 Results to be Presented at Prestigious Ocular Conference
    • iCo Therapeutics Oral Amphotericin B Published in Leading Journal
    • iCo Therapeutics Closes $1.3 Million Private Placement
    • iCo Therapeutics Closes First Tranche of Non-Brokered Private Placement
  • Category: 2010
    • iCo Therapeutics Extends Investor Relations Engagement with The Trout Group
    • iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus Royalties
    • iCo Therapeutics Reports Third Quarter 2010 Financial Results
    • iCo Therapeutics Selected as Canada’s Top 10TM Competition Winner
    • iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status
    • iCo Therapeutics Appoints Infectious Disease Experts to Scientific Advisory Board
    • iCo Therapeutics Announces Second Quarter 2010 Financial Results
    • iCo Therapeutics Inc. receives Health Canada Clearance to Conduct Phase II DME Trial with iCo-007
    • iCo Therapeutics Inc. enters into Investor Relations Engagements with The Trout Group and Sector Speak
    • iCo Therapeutics Announces First Quarter 2010 Financial Results
    • iCo Therapeutics Inc. enters into Technology Transfer Agreement with Isis Pharmaceuticals, Inc. for iCo-007
    • iCo Therapeutics iCo-007 Phase I Clinical Trial Meets Primary Endpoint
    • iCo Therapeutics Announces Year-End 2009 Financial Results
    • iCo Therapeutics Inc. engages Susan Koppy to spearhead iCo-007 out-licensing
    • iCo-007 for Diffuse Diabetic Macular Edema to be Presented at Retinal Physician Symposium 2010
    • iCo Therapeutics Inc. Recognized by BIOTECanada with Gold Leaf Award
    • iCo-007 for Diabetic Macular Edema to be Presented at Angiogenesis 2010: Clinical Trials
    • iCo Therapeutics Announces Exercise of Warrants
  • Category: 2011
    • iCo Therapeutics Announces Execution of Equity Line Facility Agreement
    • iCo Therapeutics Announces Third Quarter 2011 Financial Results
    • iCo Therapeutics Closes $1,115,000 Non-Brokered Private Placement
    • iCo Therapeutics Oral Amphotericin B Delivery System to be Presented at AAPS
    • iCo Therapeutics CEO to Present at the Ophthalmology Innovation Summit
    • iCo Therapeutics Grants Options to Directors, Officers and Employees
    • iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema
    • iCo Therapeutics CEO to Present & Act as Co-Chairperson at the 4th Annual Drug Repositioning and Pipeline Enhancement Conference
    • iCo Therapeutics CEO to Present & Act as Co-Chairperson at the 4th Annual Drug Repositioning and Pipeline Enhancement Conference
    • iCo Therapeutics Announces Second Quarter 2011 Financial Results
    • iCo Therapeutics Announces Key iCo-007 Clinical Development Milestone
    • iCo Therapeutics Announces Resignation of John Clement, Chief Technology and Development Officer and Director
    • iCo Therapeutics Engages The Equicom Group
    • iCo Therapeutics CMO to Present at The Drug Repositioning Conference
    • iCo Therapeutics Announces First Quarter 2011 Financial Results
    • iCo Therapeutics Executes Bertilimumab License with Immune Pharmaceuticals
    • iCo Therapeutics CEO to Present & Participate in Panel at BioFinance 2011
    • iCo Therapeutics Inc. Engages Ora for Ophthalmic Clinical & Regulatory Guidance
    • iCo Therapeutics Announces Year-End 2010 Financial Results
    • iCo Therapeutics Inc. Secures $10 Million Equity Line Facility
    • iCo Therapeutics Inc. iCo-007 Program to be Presented & CEO to Sit on Panel at Retinal Physician Symposium 2011
    • iCo Therapeutics Inc. Completes iCo-007 Phase 2 Clinical Supply Manufacturing
    • iCo Therapeutics Announces Year-End 2010 Financial Results
    • iCo Therapeutics Inc. Secures $10 Million Equity Line Facility
    • iCo Therapeutics Inc. iCo-007 Program to be Presented & CEO to Sit on Panel at Retinal Physician Symposium 2011
  • Category: 2012
    • iCo Therapeutics Announces Third Quarter 2012 Financial Results
    • iCo Therapeutics’ Oral Amphotericin B Delivery System to be Presented at AAPS with Updated Patent Position
    • iCo Therapeutics to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
    • iCo Therapeutics Announces Second Quarter 2012 Financial Results
    • iCo Therapeutics Closes $2.55 Million Financing
    • iCo Therapeutics to Raise $2.55 Million
    • iCo Therapeutics Announces Overnight Marketed Equity Offering
    • iCo Therapeutics receives funding from the Government of Canada for the pre-clinical and clinical development of its Oral Amphotericin B Delivery System for the treatment of HIV/AIDS
    • iCo Therapeutics Announces First Quarter 2012 Financial Results
    • iCo Therapeutics Announces Year End 2011 Financial Results
    • iCo Therapeutics and JDRF Team Up to Support Phase II Clinical Trial iDEAL for Diabetic Macular Edema
    • iCo Therapeutics CEO to Present at Retinal Physician Symposium 2012
    • iCo Therapeutics Appoints Douglas Janzen to Board of Directors
    • iCo Therapeutics Retains Crescendo Communications
  • Category: 2013
    • iCo Therapeutics Announces Overnight Marketed Equity Offering
    • iCo Therapeutics Begins Trading on the OTCQX Marketplace
    • iCo Therapeutics Announces Program and Intellectual Property Advancements for Oral Amphotericin B
    • iCo Therapeutics To Present At Jefferies Ophthalmic Therapeutic Summit
    • iCo Therapeutics Announces Third Quarter 2013 Financial Results
    • iCo Therapeutics to Present at the 6th Annual LD MICRO
    • iCo Therapeutics Announces Warrant Exercise
    • iCo Therapeutics to Present at the Ophthalmology Innovation Summit
    • iCo Therapeutics Grants Options to a Director
    • iCo Therapeutics to Present at the Rodman & Renshaw 2013 Annual Global Investment Conference
    • iCo Therapeutics Announces Second Quarter 2013 Financial Results
    • iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema
    • iCo Therapeutics Announces First Quarter 2013 Financial Results
    • iCo Therapeutics Announces Director Election Results from its Annual General Meeting of Shareholders
    • iCo Therapeutics Closes $3.4 Million Financing
    • iCo Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Conference
    • iCo Therapeutics to Raise $3.2 Million
    • iCo Therapeutics Announces Year End 2012 Financial Results
    • iCo Therapeutics Ranked Number One in Technology & Life Sciences on 2013 TSX Venture 50
    • iCo Therapeutics to Present at the 15th Annual BIO CEO & Investor Conference
    • iCo Therapeutics Grants Options to Directors, Officers and Employees
    • iCo Therapeutics Announces Positive iCo-007 Phase 2 Clinical Update
  • Category: 2014
    • iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update
    • iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS
    • iCo Therapeutics Announces Advancement of Oral Amphotericin B Program
    • iCo Therapeutics Announces Second Quarter 2014 Financial Results
    • iCo Therapeutics Announces Positive Oral Amphotericin B Study Results
    • iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders
    • iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema
    • iCo Therapeutics Announces First Quarter 2014 Financial Results
    • iCo Therapeutics Announces Poster Presentation at ARVO
    • iCo Therapeutics Announces Year End 2013 Financial Results
    • iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study
    • iCo Therapeutics Announces DTC Approval
    • iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing
    • iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing
    • iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering
  • Category: 2015
    • iCo Therapeutics Announces Changes to Board of Directors
    • iCo Therapeutics Announces Third Quarter 2015 Financial Results
    • iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program
    • iCo Therapeutics Announces Second Quarter 2015 Financial Results
    • iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders
    • iCo Therapeutics Announces First Quarter 2015 Financial Results
    • iCo Therapeutics Announces Year End 2014 Financial Results
  • Category: 2016
    • CLARIFICATION iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program
    • iCo Therapeutics Announces Third Quarter 2016 Financial Results
    • iCo Therapeutics Announces World Wide Exclusive Option and EU License Rights with Laboratorios SALVAT for Novel Glaucoma Asset
    • iCo Therapeutics Announces Second Quarter 2016 Financial Results
    • iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders
    • iCo Therapeutics Announces Year End 2015 Financial Results
    • iCo Therapeutics Inc. Announces Grant of Stock Options and Recent CEO Share Purchases
    • iCo Strategic Reorganization
  • Category: 2017
    • iCo Therapeutics Announces Third Quarter 2017 Financial Results
    • iCo Therapeutics Announces Ethics Approval for its Oral Amphotericin B Phase 1 Clinical Study
    • iCo Therapeutics Announces Upcoming Presentations and Meetings
    • iCo Therapeutics Announces Second Quarter 2017 Financial Results
    • iCo Therapeutics Inc. Approves Advance Notice Policy
    • iCo Therapeutics Announces Election of Directors
    • iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset
    • iCo Therapeutics Announces Positive Oral Amphotericin Study
    • iCo Therapeutics Announces First Quarter 2017 Financial Results
    • iCo Therapeutics Announces Year End 2016 Financial Results
    • iCo Therapeutics Inc. Announces No Material Change
  • Category: 2018
    • iCo Therapeutics Announces Third Quarter 2018 Financial Results And Corporate Update
    • iCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study
    • iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board
    • iCo Therapeutics Provides Corporate Update
    • iCo Therapeutics Announces Additional Positive Pharmacokinetic Results and Presentation at Global Investment Conference
    • iCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update
    • iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials – Phase 1 Oral Amphotericin B
    • iCo Therapeutics Announces Positive Clinical Outcome – Primary Endpoint Met in Phase 1 Oral Amphotericin B Study
    • iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment
    • iCo Therapeutics Announces First Quarter 2018 Financial Results And Update On Phase 1 Clinical Trial
    • iCo Therapeutics Announces Year End 2017 Financial Results
    • iCo Therapeutics Announces Major Milestone – Dosing of First Patient for its Oral Amphotericin B Phase 1 Clinical Study
  • Category: 2019
    • iCo Therapeutics Announces Completion of Sub-license Transfer and Full Dosing of Fifty Per Cent of Phase 1b Subjects
    • iCo Therapeutics Engages Ora for iCo-008 Ophthalmic Strategy and Pre Phase II FDA Meeting
    • iCo Therapeutics Announces Dosing of First Full Cohort in Second Oral Amphotericin B Study
    • Alexion Pharmaceuticals – iCo’s New Partner for the Development and Commercialization of iCo-008
    • iCo Therapeutics Inc. Provides an Update Regarding Oral Amphotericin Study, Marketing and Partnering Activities
    • iCo Therapeutics Provides a Corporate Update
    • iCo Therapeutics Announces Second Quarter 2019
    • iCo Therapeutics Inc. Announces the Issuance of 41,200,000 Units Pursuant to its Non-Brokered Private Placement
    • iCo Therapeutics Provides Corporate Update
    • iCo Therapeutics Announces AGM Voting Results
    • iCo Therapeutics Announces First Quarter 2019 Financial Results
    • iCo Therapeutics Announces 2018 Year End Financial
    • News & Releases
    • iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement
    • iCo Therapeutics Inc. Announces Notice of Termination of Sub License for Bertilimumab (iCo-008)
    • iCo Therapeutics Inc. Announces Upsizing of Non-Brokered Private Placement to $1,250,000 CDN
    • iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-Brokered Private Placement
    • News Releases
    • iCo Therapeutics Inc. Announces Non-Brokered Private Placement to Raise C$750,000
  • Category: 2020
    • iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical
    • iCo Therapeutics Announces Third Quarter 2020 Financial Results
    • iCo Therapeutics Announces Option Grants
    • iCo Therapeutics Inc. Announces That Oral Amphotericin B (iCo-019) Results Will Be Highlighted During the American Association of Pharmaceutical Scientists (AAPS) Virtual Meeting October 26 – November 3rd, 2020
    • iCo Therapeutics Announces Second Quarter 2020 Financial Results
    • iCo Therapeutics Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases Journal
    • iCo Therapeutics Announces First Quarter 2020 Financial Results
    • iCo Therapeutics Announces Oral Amphotericin B (iCo-019) Results to be Presented at Prestigious American Pharmaceutical Sciences Meeting and Discussion Updates
    • iCo Therapeutics Announces Q1 Interim Filing Update
    • iCo Therapeutics Announces 2019 Year End Financial Results
    • iCo Therapeutics Announces Annual Filing Update
    • iCo Therapeutics Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research
    • iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research
    • iCo Therapeutics Announces Leadership Changes
    • iCo Therapeutics Successfully Concludes Phase 1b Clinical Study Announces Positive Primary End Point for Oral Amphotericin B
    • iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing and Follow Up
    • iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing & Follow Up
    • iCo Therapeutics Inc. Proposes to Re-Price Warrants
    • iCo Therapeutics Announces Option Grants
    • iCo Therapeutics Announces Option Grants
  • Category: 2021
    • iCo Therapeutics Inc. Announces Closing of Upsized Subscription Receipt Private Placement
    • iCo Therapeutics, Inc. announces agreement for in vivo testing of iCo- 019 on SARS-CoV-2
    • iCo Therapeutics Inc. Announces Warrant Exercises
    • iCo Therapeutics Inc. Proposes to Re-Price Warrants
  • Category: Press Releases
Contact Us  About iCo

 Sitemap
© Copyright 2022 - iCo Therapeutics Inc. - All Rights Reserved.